+91-98 455 710 46 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
11 May 2021

Eli Lilly to partner with Cipla, Lupin, Sun Pharma to manufacture, distribute Baricitinib in India

/
Posted By
/
Comments0
/

US drug-maker Eli Lilly, on May 10, announced that it had issued royalty-free, non-exclusive voluntary licenses to established Indian pharmaceutical manufacturers of generic medicines, Cipla, Lupin and Sun Pharmaceutical Industries to manufacture and distribute Baricitinib in India.

Lilly said it was also in discussions with several other Indian manufacturers for the potential grant of additional voluntary licenses.

Baricitinib was issued a restricted emergency use approval by the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India for use in combination with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.